ライフサイエンスコーパス: papilledema

1 hy, optic neuropathies caused by tumors, and papilledema.

2 31 patients (89%) had papilledema.

3 Five patients (1.7%) had papilledema.

4 Fundus examination revealed papilledema.

5 s and among asymptomatic individuals without papilledema.

6 MRI in this study but rarely associated with papilledema.

7 sultations and accelerate the evaluation for papilledema.

8 layed high AUCs for differentiating TOD from papilledema.

9 n, abnormal pupillary responses, or signs of papilledema.

10 with cerebral vein thrombosis (CVT) without papilledema.

11 r causing elevated intracranial pressure and papilledema.

12 demyelinating polyneuropathy and concurrent papilledema.

13 volume swelling measurements resulting from papilledema.

14 erentiating features between buried ONHD and papilledema.

15 able in differentiating buried ONHD and mild papilledema.

16 tained at the same visit in 15 patients with papilledema.

17 rements from SD-OCT volumes of subjects with papilledema.

18 OCT in patients after resolution of SRF and papilledema.

19 algorithm can be used to automatically grade papilledema.

20 headache and slightly blurred vision due to papilledema.

21 ne which children warrant further workup for papilledema.

22 onounced in the eye with the higher grade of papilledema.

23 e also decreased in patients with high-grade papilledema.

24 atively depressed in the eye with high-grade papilledema.

25 duced in at least one quadrant in 1 eye with papilledema, 1 eye with optic neuritis, and in 13 eyes w

26 re optic neuritis or optic neuropathy (21%), papilledema (18%), diplopia or cranial nerve palsies (16

27 atrophy eyes (7.9%) (1 retinal vasculitis, 3 papilledema, 2 infiltrative optic neuropathy).

28 Of 30 eyes with papilledema, 20 eyes (67%) had positive RPE/BM rim angle

29 P were used to prospectively study eyes with papilledema (24), optic neuritis (14), nonarteritic ante

30 ] 10.21, P < .0053) and cases with worsening papilledema (3.5, P < .043) were associated with permane

31 uritis, 11 anterior visual pathway tumors, 2 papilledema, 3 other) (P < .0001).

32 l abnormalities (1.4 vs. 7.8, p = .039), and papilledema (31% vs. 13%, p = .003) were also more commo

33 Forty-two eyes with mild papilledema, 37 eyes with congenitally elevated optic di

34 (SD 9.7), RNFL 364 um (SD 128), Frisen grade papilledema 4.3 (SD 0.9).

35 e most common ED referral questions were for papilledema (75 of 322 [23%]) and vision loss (72 of 322

36 e IIH, and 1 as having suspected IIH without papilledema; 77 did not have IIH and served as controls,

37 In patients with active papilledema a significant elevation of the center of the

38 The shape difference in papilledema, absent in AION, cannot be explained by disc

39 ier used these features to assign a grade of papilledema according to a standard protocol used by an

40 the right and left eyes of 39 subjects with papilledema acquired over the span of 2 years were used.

41 ts (90 eyes) were included, 11 patients with papilledema and 34 with pseudopapilledema.

42 Ophthalmologic manifestations of IIH such as papilledema and abducens nerve palsy are well recognized

43 In children and young adults with papilledema and elevated intracranial pressure causing v

44 T volume could reliably differentiate NAION, papilledema and healthy eyes.

45 nt articles have reported the association of papilledema and hypoparathyroidism, However, very rarely

46 schemic optic neuropathy (AION), and 25 with papilledema and intracranial hypertension.

47 ster in normal subjects and in patients with papilledema and ischemic optic neuropathy.

48 er cells +++, bilateral synechiae, bilateral papilledema and macular edema associated with serous ret

49 verage RNFL by OCT was similar for eyes with papilledema and NAION (P = 0.97), and reduced for optic

50 earning system was able to reliably identify papilledema and normal optic discs on nonmydriatic photo

51 erage RNFL by SLP was slightly increased for papilledema and optic neuritis, and reduced for NAION (P

52 Papilledema and PMD recovered but GCL atrophy continued

53 ickness between both groups of patients with papilledema and pseudopapilledema and normal subjects.

54 er peripapillary total retinal volume in the papilledema and pseudopapilledema groups were 2.68 +/- 0

55 We identified OCT-derived biomarkers for papilledema and pseudopapilledema in the existing litera

56 treatment, there was complete resolution of papilledema and retinal haemorrhages in both eyes.

57 uate correlations between retinal thickness, papilledema and VA.

58 of retinal thinning and the correlation with papilledema and visual acuity (VA) in a large population

59 All patients with papilledema and visual field deficits also exhibited imp

60 All patients with papilledema and visual field deficits also exhibited imp

61 , a higher chance of incidentally identified papilledema, and body mass index similar to that of youn

62 deep learning system ("normal optic discs," "papilledema," and "other optic disc abnormalities").

63 umbar puncture unless concerning symptoms or papilledema are present.

64 atients (10%) with IIH and highly asymmetric papilledema, as defined by an interocular difference of

65 Papilledema at diagnosis was associated with perioptic s

66 ngth of stay of patients being evaluated for papilledema by 56% and mostly avoided in-person ophthalm

67 the degree of disc swelling in subjects with papilledema can be obtained from SD-OCT volumes, with th

68 Papilledema can progress despite appropriate therapy.

69 nexpected neurotoxicity, including seizures, papilledema, cauda equina syndrome (n = 2), and encephal

70 Visual loss in patients with asymmetric papilledema caused by IIH was most pronounced in the eye

71 rve fiber layer (RNFL) findings in eyes with papilledema caused by raised intracranial pressure to fi

72 In five patients with active papilledema, CSL tomography was performed serially over

73 Papilledema describes optic nerve head (ONH) swelling du

74 f these patients, 9 (29%) had progression of papilledema despite treatment, 17 patients (55%) did not

75 s do not meet LPOP criteria (with or without papilledema), despite having IIH-related symptoms and ne

76 valence of MRI signs of IH and prevalence of papilledema detected on ocular fundus photographs.

77 The average time from CVST diagnosis to papilledema documentation was 29 days with a mean (SD) i

78 ome measures included time from diagnosis to papilledema documentation, papilledema progression, time

79 to evaluate for the presence and severity of papilledema, due to intracranial hypertension.

80 y reduce VA or cause VF defects unrelated to papilledema, emphasizing the importance of a detailed di

81 The papilledema-estimating MRI score showed optimal balance

82 The other important features include papilledema, extravascular volume overload, sclerotic bo

83 e curve to discriminate pseudopapilledema vs papilledema eyes for average RNFL thickness and inner an

84 On follow-up, 22 papilledema eyes had a reduction of RNFL swelling, and 1

85 n to be worse in the eye with the high-grade papilledema for all outcome measures.

86 ived serial eye examinations with documented papilledema from 2008-2016.

87 eference plane and also to expert grading of papilledema from digital fundus photographs using the Fr

88 were developed to analyze three features of papilledema from digital fundus photographs: (1) sharpne

89 learning (DL) has been used to differentiate papilledema from healthy eyes and optic disc elevation o

90 %] and specificity 89.6% [86.3%-92.8%]), and papilledema from normal and others (AUC 0.97 [0.95-0.99]

91 ding qualitative biomarkers to differentiate papilledema from ODD and COD demonstrated a sensitivity

92 sensitivity and specificity to differentiate papilledema from ODD and COD.

93 OFA cannot definitively distinguish papilledema from pseudopapilledema in children and shoul

94 c imaging method conclusively differentiated papilledema from pseudopapilledema in children because o

95 strates promising utility in differentiating papilledema from pseudopapilledema.

96 g volumes might be useful in differentiating papilledema from pseudopapilledema.

97 In a model differentiating papilledema from TOD, the best-performing biomarker achi

98 Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.

99 The relationship between papilledema grade and visual loss is unclear.

100 mine whether there is a relationship between papilledema grade and visual loss.

101 Mean improvements in papilledema grade occurred most markedly in the group th

102 iber layer (RNFL) thickness, ONH volume, and papilledema grade were measured.

103 (MD) with secondary measures being change in papilledema grade, ETDRS scores, and quality-of-life (Qo

104 to the placebo group significantly improved papilledema grade, headache, and QoL measures.

105 ondary outcome variables included changes in papilledema grade, quality of life (Visual Function Ques

106 reduction in RNFL thickness, ONH volume, and papilledema grade.

107 months show only moderate correlations with papilledema grade.

108 Subjects underwent perimetry, papilledema grading (Frisen method), high- and low-contr

109 ith patients without papilledema, those with papilledema had a significantly higher body mass index a

110 system could have improved the detection of papilledema had it been available to ED providers as a r

111 At 4 months postoperatively, papilledema had resolved.

112 away from the vitreous; the RPE/BM layer in papilledema has an inverted U shape, skewed nasally inwa

113 ptic nerve alterations like optic atrophy or papilledema have been described.

114 The sustained improvements in papilledema, headache, and visual symptoms, coupled with

115 sessed at 3, 6, 12, and 24 months, including papilledema, headache, visual symptoms, and therapeutic

116 test normal and fundus examination found no papilledema images.

117 Six patients with missed papilledema in 1 eye were correctly identified by the de

118 The most common abnormal findings were papilledema in 86 of 164 patients (52.4%) who underwent

119 e cost-effective diagnosis and management of papilledema in a telemedical setting.

120 ce in RNFL thickness between buried ONHD and papilledema in any of the 4 quadrants.

121 n the natural history and visual outcomes of papilledema in children with CVST.

122 % CI, 70%-100%) with a clinical diagnosis of papilledema in children.

123 A longer duration of papilledema in early childhood correlated with an increa

124 A longer duration of papilledema in early childhood correlated with an increa

125 the magnitude and monitor the resolution of papilledema in PTC.

126 tified by the deep learning system as having papilledema in the other eye.

127 E and EMBASE, we included case reports with "papilledema" in their title, abstract, or article keywor

128 Papilledema incidence was consistently lower in the bari

129 The prevalence of papilledema increased from 2.8% among patients with at l

130 uveitis IRR, 13.9; other uveitis IRR, 43.0; papilledema IRR, 38.3).

131 Papilledema is a leading reason for referral to neuro-op

132 The term "papilledema" is often misused in different ways when des

133 "Papilledema" is widely misused even among ophthalmology

134 serum calcium correction effectively treats papilledema, its benefit for optic neuritis remains uncl

135 Funduscopy showed a bilateral papilledema, juxtapapillary exudates and splinter hemorr

136 doscopic examination showed moderate grade 3 papilledema, left greater than right, with obscuration o

137 If managed inappropriately, papilledema may cause permanent vision loss.

138 sinus stenosis can estimate the presence of papilledema more accurately than the current diagnostic

139 In any specialty setting, papilledema must be distinguished from other causes of O

140 01), more frequent incidental discoveries of papilledema (n = 19 [29.2%] vs. controls: 7 [10.8%]; P =

141 maculopathy (n = 9 [5.6%])-or by ruling out papilledema (n = 52 [32.1%]).

142 ges (n = 13 [8.0%]), papilledema or rule out papilledema (n = 60 [37.0%]), painless red eye (n = 7 [4

143 ned as stable VA within 1 logMAR line and no papilledema on fundoscopy for at least 4 months followin

144 vidence of elevated ICP), type 2 (declaring "papilledema" on examination before finding evidence of e

145 213 patients with confirmed papilledema, optic disc drusen (ODD), tilted optic discs

146 Emergency department (ED) visits to rule out papilledema or for papilledema workup are increasing.

147 .5%]), other visual changes (n = 13 [8.0%]), papilledema or rule out papilledema (n = 60 [37.0%]), pa

148 further follow-up depending on the level of papilledema or vision changes.

149 history of ICH based on direct measurement, papilledema, or classic features on neuroimaging and dur

150 mental status, focal neurological deficits, papilledema, or history of immunocompromising conditions

151 ogy consultations in the ED were concern for papilledema, other optic disc swelling, and optic neurit

152 a crease in the outer retina associated with papilledema owing to idiopathic intracranial hypertensio

153 , it was not correlated with the duration of papilledema (P = .95).

154 Retinal surface elevation among papilledema patients obtained from stereo fundus photogr

155 g modality for classifying pediatric eyes as papilledema (PE) or pseudopapilledema (PPE).

156 with the neuro-ophthalmologist when grading papilledema per patient.

157 Patients with IIH with sight-threatening papilledema presenting to a single United Kingdom neuros

158 In 21.5% of cases, papilledema progressed over an average of 55.6 (56.6) da

159 from diagnosis to papilledema documentation, papilledema progression, time to papilledema resolution,

160 camera in our ED (NMFP-OCT) combined with a "papilledema protocol" could avoid in-person ophthalmolog

161 er peripapillary total retinal volume in the papilledema, pseudopapilledema, and control groups were

162 "Papilledema" refers to ODE secondary to raised intracran

163 rious types of retinal folds associated with papilledema reflect biodynamic processes and show an ACZ

164 The development of papilledema requires high cerebrospinal fluid (CSF) pres

165 Time to papilledema resolution was approximately 6 months.

166 umentation, papilledema progression, time to papilledema resolution, treatment interventions and fina

167 eatment, and final visual outcomes following papilledema resolution.

168 Among 26 patients with follow-up, papilledema resolved in 107 +/- 128 days.

169 ved posteriorly into a normal V shape as the papilledema resolved with weight loss or shunting.

170 and optical coherence tomography measures of papilledema (retinal nerve fiber layer [RNFL]) and macul

171 In five eyes with papilledema, RNFL thickening increased, three of which d

172 ole (ROR = 20.90, 95% CI = 2.65-165.01), and papilledema (ROR = 6.97, 95% CI = 2.53-19.17) (all P <=

173 at from OCT scans and with expert grading of papilledema severity.

174 - and posttreatment OCTs, in select cases of papilledema, showed that the inverted U-shaped RPE/BM mo

175 the amount of RNFL swelling, and resolves as papilledema subsides.

176 eformation of the disc (i.e., a reduction in papilledema) that was initially apparent in the temporal

177 For patients referred to the ED for papilledema, the ED NMFP-OCT camera reduced the median E

178 In papilledema, the RPE/BM is commonly deflected inward, in

179 Compared with patients without papilledema, those with papilledema had a significantly

180 rds were reviewed for presence and course of papilledema, treatment, and final visual outcomes follow

181 ows: (number of eyes correctly identified as papilledema [true positive] + number of eyes correctly i

182 for inpatient consultations were concern for papilledema, visual field defects, and diplopia.

183 In patients with high-grade papilledema, visual loss appeared to affect the entire v

184 Our findings showed that high-grade papilledema was associated with visual dysfunction in pa

185 An MRI score estimating papilledema was calculated using machine learning.

186 with IIH were reviewed, and their degree of papilledema was graded using Frisen's scheme.

187 Papilledema was more common among patients with a JCH co

188 ion of cerebral radiological diagnostics and papilledema was performed.

189 Papilledema was present on initial presentation in 54% o

190 need in-person consultations either because papilledema was ruled out remotely on ocular imaging in

191 d in-person ophthalmology consultations when papilledema was ruled out remotely on ocular imaging, re

192 ation of the ED NMFP-OCT camera (P = 0.007); papilledema was ruled out remotely without in-person oph

193 stay in hours and number of patients in whom papilledema was ruled out remotely.

194 For the 199 patients in whom papilledema was ruled out with the NMFP-OCT camera, the

195 lar imaging in 220 patients or because known papilledema was stable or improved on remote review of o

196 erior ischemic optic neuropathy (NAION) from papilledema, we hypothesized that a DL approach using th

197 and quantitative assessment of the stage of papilledema with accuracy that is comparable to grading

198 s can show delayed onset and/or worsening of papilledema with time.

199 ded for the following errors: type 1 (using "papilledema" without evidence of elevated ICP), type 2 (

200 t (ED) visits to rule out papilledema or for papilledema workup are increasing.